Compare Cassava Sciences Inc (FLNA) vs ServiceNow Inc (NOW) Price & Performance

FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.

Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.

ServiceNow (NOW) trades at $104.85, down 5.76% over the past day, with a neutral technical signal. The stock shows strong fundamentals, with revenue growing from $7.2B in 2022 to $13.3B in 2025 and a robust gross profit margin of 76.56%. Recent earnings have mostly beaten expectations, and the company maintains positive operating cash flow. Analyst sentiment is overwhelmingly bullish, with an 85.51% buy rating and a consensus price target of $137.52, suggesting significant upside potential from current levels.

The outlook for NOW is positive, driven by its leadership in enterprise AI solutions and consistent financial performance. Investment opportunities include exposure to high-growth AI markets and strong cash generation. Key risks involve elevated valuation multiples, competitive pressures in the SaaS sector, and execution challenges in sustaining growth. The stock presents a compelling case for growth-oriented investors, though its high P/E ratio warrants caution amid market volatility.